Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia.

doi:10.1186/s12943-023-01907-7

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia.

Molecular cancer - 4 Dec 2023

Tubío-Santamaría Nuria, Jayavelu Ashok Kumar, Schnoeder Tina M, Eifert Theresa, Hsu Chen-Jen, Perner Florian, Zhang Qirui, Wenge Daniela V, Hansen Fynn M, Kirkpatrick Joanna M, Jyotsana Nidhi, Lane Steven W, von Eyss Björn, Deshpande Aniruddha J, Kühn Michael W M, Schwaller Juerg, Cammann Clemens, Seifert Ulrike, Ebstein Frédéric, Krüger Elke, Hochhaus Andreas, Heuser Michael, Ori Alessandro, Mann Matthias, Armstrong Scott A, Heidel Florian H

Abstract excerpt

Pharmacologic targeting of chromatin-associated protein complexes has shown significant responses in KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML) but resistance frequently develops to single agents. This points to a need for therapeutic combinations that target multiple mechanisms. To enhance our understanding of functional dependencies in KMT2A-r AML, we have used a proteomic approach to identify the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression

Share to Leukemia, Myeloid, Acute

Share to Mice

Share to Mutation

Share to Myeloid-Lymphoid Leukemia Protein

Share to Proteomics

Share to Transcription Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 38049829
DOI: 10.1186/s12943-023-01907-7
PMCID: PMC10694946

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia.PMID 38049829Read ↗

Bleximenib, the novel menin-KMT2A inhibitor JNJ-75276617, impairs long-term proliferation and immune evasion in acute myeloid leukemiaSemantic proximity Read ↗

Therapeutic Targeting of the Menin–KMT2A InteractionSemantic proximity Read ↗

Targeting Chromatin Complexes in Myeloid Malignancies and Beyond: From Basic Mechanisms to Clinical InnovationSemantic proximity Read ↗

SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML.Semantic proximity Read ↗

Expression of immunoproteasome genes is regulated by cell-intrinsic and –extrinsic factors in human cancersSemantic proximity Read ↗

Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemiaSemantic proximity Read ↗

SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AMLSemantic proximity Read ↗

Targeting the Menin-KMT2A Axis in Acute Leukemia: From Epigenetic Dependency to Clinical Translation.Semantic proximity Read ↗

Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapiesSemantic proximity Read ↗

Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.Semantic proximity Read ↗

Acute Myeloid Leukemias with Alterations of Lysine Methyltransferase 2A (KMT2A): Recent Therapeutic DevelopmentsSemantic proximity Read ↗

Automated CUT&Tag profiling of chromatin heterogeneity in mixed-lineage leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.